LimFlow SA has announced the appointment of Mike Mathias as Vice President of Commercial Operations. The company is a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI).
LimFlow has appeared on our pages a number of times in recent years. The company’s minimally-invasive LimFlow system is designed to bypass blocked arteries in the leg. As a result it delivers oxygenated blood back into the foot via the veins. For patients, restoring perfusion in the lower limbs has many benefits. In particular it can resolve chronic pain, improve quality of life, enable wound healing and prevent major amputation.
Newly appointed Vice President of Commercial Operations, Mike Mathias has spent his 30-year career successfully leading sales organizations in the cardiovascular space. This has including playing a seminal role in the launch of Medtronic’s transcatheter aortic valve replacement (TAVR) business as head of the company’s $1.2 billion Heart Valve Therapies U.S. sales operation.
Most recently, Mr. Mathias was Vice President of U.S. Commercial Operations for the Medtronic Structural Heart division, leading sales, marketing, training, and sales operations. Prior to this, he held sales management roles across Medtronic’s cardiology, endovascular, cardiac surgery, peripheral, perfusion and cardiac rhythm businesses. He also performed a variety of sales roles in the cardiology franchise for Pfizer. He earned a B.S. in Arabic and French Studies at the U.S. Military Academy at West Point. Furthermore he holds a master’s degree in Business Administration from the University of Minnesota.
“Mike is an extraordinary leader with deep experience building successful sales teams and commercializing innovations. Examples include TAVR, where he introduced a transformational new device and therapy into a complex market development setting in the U.S.,” said LimFlow CEO Dan Rose. “The magnitude of our opportunity at LimFlow has enabled us to attract the highest level of talent to our team. We look forward to benefitting from Mike’s insights and sales leadership as we build our commercial organization and prepare for the future launch of the LimFlow System in the U.S.”
Mr Mathias states; “I see many parallels between LimFlow and the groundbreaking solution that TAVR represented for both patients and physicians. LimFlow can be an equally revolutionary therapy with the potential to significantly reduce amputations due to end-stage vascular disease and change the course of patient care.
“The patient-centric culture of execution at LimFlow combined with the collaborative nature of the skilled team provides a strong foundation to build the U.S. commercial organization at LimFlow.”
In line with LimFlow’s broader growth strategy, Theo Mastrokostopoulos, currently Vice President of Global Sales and Market Development, is being appointed to General Manager, International to lead all commercial activity outside of the U.S.
Click here to view a video of how the LimFlow System for deep vein arterialization works.